Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases

Overview

Journal Front Pharmacol

Date 2022 Jun 2

PMID 35652048

Authors

Jianglei Li

Meihong Yu

Shifeng Fu

Deliang Liu

Yuyong Tan

Affiliations

Soon will be listed here.

Abstract

The deacetylation process regulated by histone deacetylases (HDACs) plays an important role in human health and diseases. HDAC6 belongs to the Class IIb of HDACs family, which mainly modifies non-histone proteins located in the cytoplasm. HDAC6 plays a key role in tumors, neurological diseases, and inflammatory diseases. Therefore, targeting HDAC6 has become a promising treatment strategy in recent years. ACY-1215 is the first orally available highly selective HDAC6 inhibitor, and its efficacy and therapeutic effects are being continuously verified. This review summarizes the research progress of ACY-1215 in cancer and other human diseases, as well as the underlying mechanism, in order to guide the future clinical trials of ACY-1215 and more in-depth mechanism researches.

Citing Articles

Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein-Protein Interactions.

Asaad L, Pepperrell B, McErlean E, Furlong F Int J Mol Sci. 2025; 26(3).

PMID: 39941046 PMC: 11818932. DOI: 10.3390/ijms26031274.

Histone deacetylase 6 inhibition prevents hypercholesterolemia-induced erectile dysfunction independent of changes in markers of autophagy.

Ihrig C, Montgomery M, Nomura Y, Nakano M, Pandey D, La Favor J Sex Med. 2025; 12(6):qfae096.

PMID: 39790566 PMC: 11717367. DOI: 10.1093/sexmed/qfae096.

The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy.

Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N Sci Adv. 2024; 10(46):eadp3687.

PMID: 39546602 PMC: 11566997. DOI: 10.1126/sciadv.adp3687.

Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options.

Mallick-Searle T, Adler J J Pain Res. 2024; 17:1005-1028.

PMID: 38505500 PMC: 10949339. DOI: 10.2147/JPR.S442595.

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer.

Vuletic A, Mirjacic Martinovic K, Spasic J Pharmaceutics. 2024; 16(1).

PMID: 38258065 PMC: 10818982. DOI: 10.3390/pharmaceutics16010054.

References

Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M . Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019; 14:5541-5554. PMC: 6650620. DOI: 10.2147/IJN.S200490. View

Benoy V, Vanden Berghe P, Jarpe M, Van Damme P, Robberecht W, Van Den Bosch L . Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2016; 14(2):417-428. PMC: 5398982. DOI: 10.1007/s13311-016-0501-z. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

Chen Q, Wang Y, Jiao F, Cao P, Shi C, Pei M . HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway. J Cell Mol Med. 2021; 25(15):7218-7228. PMC: 8335684. DOI: 10.1111/jcmm.16751. View

Gao S, Wang Z, Ma J, Wang J, Xing X, Shen C . Effect of ACY-1215 on cytoskeletal remodeling and histone acetylation in bovine somatic cell nuclear transfer embryos. Theriogenology. 2022; 183:98-107. DOI: 10.1016/j.theriogenology.2022.02.018. View

Yu X, Guo Z, Marcu M, Neckers L, Nguyen D, Chen G . Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002; 94(7):504-13. DOI: 10.1093/jnci/94.7.504. View

Huang P, Almeciga-Pinto I, Jarpe M, van Duzer J, Mazitschek R, Yang M . Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget. 2016; 8(2):2694-2707. PMC: 5356834. DOI: 10.18632/oncotarget.13738. View

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

10.

Chen X, Yu C, Hou X, Li J, Li T, Qiu A . Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy. Am J Physiol Renal Physiol. 2020; 319(6):F1003-F1014. PMC: 7792693. DOI: 10.1152/ajprenal.00261.2020. View

11.

Avdoshina V, Caragher S, Wenzel E, Taraballi F, Mocchetti I, Harry G . The viral protein gp120 decreases the acetylation of neuronal tubulin: potential mechanism of neurotoxicity. J Neurochem. 2017; 141(4):606-613. PMC: 5815513. DOI: 10.1111/jnc.14015. View

12.

Cao W, Shen R, Richard S, Liu Y, Jalalirad M, Cleary M . Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt. Oncol Rep. 2021; 47(2). PMC: 8759100. DOI: 10.3892/or.2021.8252. View

13.

Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D . In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002; 21(24):6820-31. PMC: 139102. DOI: 10.1093/emboj/cdf682. View

14.

Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A . Histone acetylation and disease. Cell Mol Life Sci. 2001; 58(5-6):728-36. PMC: 11337357. DOI: 10.1007/pl00000896. View

15.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

16.

Sharma S, Sarathlal K, Taliyan R . Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases. CNS Neurol Disord Drug Targets. 2018; 18(1):11-18. DOI: 10.2174/1871527317666181004155136. View

17.

Miyake K, Takano N, Kazama H, Kikuchi H, Hiramoto M, Tsukahara K . Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. Int J Oncol. 2022; 60(5). PMC: 8997343. DOI: 10.3892/ijo.2022.5344. View

18.

Oba T, Ono M, Matoba H, Uehara T, Hasegawa Y, Ito K . HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells. Breast Cancer Res Treat. 2021; 186(1):37-51. DOI: 10.1007/s10549-020-06033-2. View

19.

Lin C, Hsu K, HuangFu W, Lin T, Huang H, Pan S . Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury. BMC Pharmacol Toxicol. 2020; 21(1):21. PMC: 7077123. DOI: 10.1186/s40360-020-0400-0. View

20.

Zhang W, Zhang H, Wang Y, Jiao F, Wang L, Gong Z . Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice. Front Pharmacol. 2019; 10:653. PMC: 6581020. DOI: 10.3389/fphar.2019.00653. View